Ezra Y. Rosen
Memorial Sloan Kettering Cancer Center · 211 works · 3,326 citations · h-index 19
Top works
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- Tumour lineage shapes BRCA-mediated phenotypes
- Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers
- TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
- Functional Genomic Analyses Identify Pathways Dysregulated by Progranulin Deficiency, Implicating Wnt Signaling
- The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
- Characterization of on-target adverse events caused by TRK inhibitor therapy
- Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
- Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
- A Performance Comparison of Commonly Used Assays to Detect RET Fusions
- Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
- Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
- Genome-Wide Analysis of a Wnt1-Regulated Transcriptional Network Implicates Neurodegenerative Pathways
- Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma
- Author Correction: Tumour lineage shapes BRCA-mediated phenotypes
- Abstract B001: Identification of monoallelic ATM loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy
- Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance
- Precision Oncology: 2022 in Review